{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:49:32Z","timestamp":1791571772986,"version":"4.3.4"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Intravenous paclitaxel, 100 mg\/m<jats:sup>2<\/jats:sup>, given over 3 hours every 2 weeks is associated with a response rate of 59% in patients with recurrent or refractory acquired immunodeficiency syndrome (AIDS)\u2010related Kaposi sarcoma (KS). However, this regimen is associated with significant myelosuppression, and the inconvenience of a 3\u2010hour infusion. Moreover, no effective therapies have been defined for use after treatment failure with this agent. A Phase II trial was conducted with weekly docetaxel in patients with advanced\u2010stage KS to assess safety and antitumor activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Docetaxel was administered at a dose of 25 mg\/m<jats:sup>2<\/jats:sup> intravenously over 15\u201330 minutes weekly for 8 weeks. Thereafter, if the patient experienced stable disease or better response, treatment doses were given every other week until complete disease remission, disease progression, or unacceptable toxicity occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Twelve patients were accrued\u20149 had &gt; 25 mucocutaneous lesions, 1 had lymphedema, and 2 had visceral involvement. Ten patients (83%) had previous systemic chemotherapy, including 4 who received previous paclitaxel. Treatment was well tolerated, with no Grade 4 toxicity of any type. Grade 3 neutropenia occurred in 33% of patients but no patient had neutropenic fever. Five patients (42%) achieved a partial response, including 1 who had previously failed to respond to paclitaxel. The median time to disease progression was 26 months (range, 5\u201353 months). With a median follow\u2010up period of 45 months, the median survival point had not been reached.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Weekly docetaxel is safe, with reasonable antitumor activity in patients with advanced\u2010stage, recurrent, or refractory AIDS\u2010related KS. Cancer 2005. \u00a9 2004 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.20780","type":"journal-article","created":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T12:49:56Z","timestamp":1101905396000},"page":"417-421","source":"Crossref","is-referenced-by-count":41,"title":["Weekly docetaxel is safe and effective in the treatment of advanced\u2010stage acquired immunodeficiency syndrome\u2010related Kaposi sarcoma"],"prefix":"10.1002","volume":"103","author":[{"given":"Soon Thye","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Tupule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron M.","family":"Espina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,1,5]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2445"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.683"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2353"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.1999.17.6.1876","article-title":"Paclitaxel is safe and effective in the treatment of advanced AIDS\u2010related Kaposi's sarcoma","volume":"6","author":"Gill PS","year":"1999","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_6_2","first-page":"47a","article-title":"Activity of Taxotere (docetaxel) as therapy for pretreated HIV\u2010associated Kaposi's sarcoma (KS): an ANRS trial","volume":"17","author":"Boue F","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/JCO.2001.19.15.3500","article-title":"Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial","volume":"15","author":"Hainsworth JD","year":"2001","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1201"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1200\/JCO.2000.18.14.2733","article-title":"Docetaxel for patients with paclitaxel\u2010resistant mullerian carcinoma","volume":"14","author":"Verschraegen CF","year":"2000","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3362"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00002"},{"key":"e_1_2_5_12_2","first-page":"236","article-title":"Regression of AIDS\u2010related Kaposi's sarcoma following ritonavir therapy","volume":"34","author":"Diz Dios P","year":"1998","journal-title":"Oral Oncol."},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg050"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.319.7201.23"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.22.1823"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00126334-200007010-00013","article-title":"Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy","volume":"3","author":"Jones JL","year":"2000","journal-title":"J Acquir Immune Defic Syndr."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20780","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:13:51Z","timestamp":1760289231000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,5]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,1,15]]}},"alternative-id":["10.1002\/cncr.20780"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20780","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,5]]}}}